Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. more
Time Frame | ATAI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.5% | -1.8% | -0.77% |
1-Month Return | -6.33% | -3.48% | 0.71% |
3-Month Return | 18.4% | -7.2% | 8.81% |
6-Month Return | 12.12% | -1.54% | 12.32% |
1-Year Return | 28.7% | 8.39% | 30.57% |
3-Year Return | -86.57% | 6.07% | 29.21% |
5-Year Return | -92.39% | 44.07% | 91.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 19.88M | 20.38M | 233.00K | 314.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":97.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.14,"profit":true},{"date":"2023-12-31","value":1.54,"profit":true}] |
Cost of Revenue | 6.00K | 24.00K | 47.00K | 168.00K | 319.00K | [{"date":"2019-12-31","value":1.88,"profit":true},{"date":"2020-12-31","value":7.52,"profit":true},{"date":"2021-12-31","value":14.73,"profit":true},{"date":"2022-12-31","value":52.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (6.00K) | (24.00K) | 20.33M | 65.00K | 314.00K | [{"date":"2019-12-31","value":-0.03,"profit":false},{"date":"2020-12-31","value":-0.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.32,"profit":true},{"date":"2023-12-31","value":1.54,"profit":true}] |
Gross Margin | - | (0.12%) | 99.77% | 27.90% | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.12,"profit":false},{"date":"2021-12-31","value":99.77,"profit":true},{"date":"2022-12-31","value":27.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 8.17M | 92.14M | 140.70M | 144.66M | 125.78M | [{"date":"2019-12-31","value":5.65,"profit":true},{"date":"2020-12-31","value":63.69,"profit":true},{"date":"2021-12-31","value":97.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.95,"profit":true}] |
Operating Income | 1.57M | (104.16M) | (135.81M) | (144.79M) | (125.47M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-6617.66,"profit":false},{"date":"2021-12-31","value":-8628.02,"profit":false},{"date":"2022-12-31","value":-9198.67,"profit":false},{"date":"2023-12-31","value":-7971.47,"profit":false}] |
Total Non-Operating Income/Expense | (19.02M) | (74.09M) | (591.00K) | 10.15M | 85.60M | [{"date":"2019-12-31","value":-22.23,"profit":false},{"date":"2020-12-31","value":-86.55,"profit":false},{"date":"2021-12-31","value":-0.69,"profit":false},{"date":"2022-12-31","value":11.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (17.47M) | (101.81M) | (136.60M) | (135.18M) | (39.29M) | [{"date":"2019-12-31","value":-1747400000,"profit":false},{"date":"2020-12-31","value":-10181300000,"profit":false},{"date":"2021-12-31","value":-13660100000,"profit":false},{"date":"2022-12-31","value":-13518200000,"profit":false},{"date":"2023-12-31","value":-3928600000,"profit":false}] |
Income Taxes | 2.00K | 305.00K | (3.99M) | 6.23M | 1.02M | [{"date":"2019-12-31","value":0.03,"profit":true},{"date":"2020-12-31","value":4.9,"profit":true},{"date":"2021-12-31","value":-64.04,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":16.31,"profit":true}] |
Income After Taxes | (17.48M) | (102.12M) | (132.61M) | (141.41M) | (40.30M) | [{"date":"2019-12-31","value":-1747600000,"profit":false},{"date":"2020-12-31","value":-10211800000,"profit":false},{"date":"2021-12-31","value":-13261200000,"profit":false},{"date":"2022-12-31","value":-14141100000,"profit":false},{"date":"2023-12-31","value":-4030200000,"profit":false}] |
Income From Continuous Operations | (24.38M) | (178.63M) | (174.24M) | (141.41M) | (71.40M) | [{"date":"2019-12-31","value":-2438400000,"profit":false},{"date":"2020-12-31","value":-17862500000,"profit":false},{"date":"2021-12-31","value":-17424400000,"profit":false},{"date":"2022-12-31","value":-14141100000,"profit":false},{"date":"2023-12-31","value":-7140200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.48M) | (102.12M) | (132.61M) | (141.41M) | (40.22M) | [{"date":"2019-12-31","value":-1747600000,"profit":false},{"date":"2020-12-31","value":-10211800000,"profit":false},{"date":"2021-12-31","value":-13261200000,"profit":false},{"date":"2022-12-31","value":-14141100000,"profit":false},{"date":"2023-12-31","value":-4022400000,"profit":false}] |
EPS (Diluted) | 0.16 | 0.01 | (1.77) | (0.98) | (0.82) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":3.24,"profit":true},{"date":"2021-12-31","value":-1124.52,"profit":false},{"date":"2022-12-31","value":-622.62,"profit":false},{"date":"2023-12-31","value":-520.97,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ATAI | |
---|---|
Cash Ratio | 2.29 |
Current Ratio | 5.81 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ATAI | |
---|---|
ROA (LTM) | -25.41% |
ROE (LTM) | -62.77% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ATAI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ATAI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 806.06 |
P/B | 1.80 |
Price/FCF | NM |
EV/R | 603.20 |
EV/Ebitda | 0.27 |
ATAI Life Sciences BV (ATAI) share price today is $1.48
Yes, Indians can buy shares of ATAI Life Sciences BV (ATAI) on Vested. To buy ATAI Life Sciences BV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATAI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of ATAI Life Sciences BV (ATAI) via the Vested app. You can start investing in ATAI Life Sciences BV (ATAI) with a minimum investment of $1.
You can invest in shares of ATAI Life Sciences BV (ATAI) via Vested in three simple steps:
The 52-week high price of ATAI Life Sciences BV (ATAI) is $2.85. The 52-week low price of ATAI Life Sciences BV (ATAI) is $1.03.
The price-to-earnings (P/E) ratio of ATAI Life Sciences BV (ATAI) is
The price-to-book (P/B) ratio of ATAI Life Sciences BV (ATAI) is 1.80
The dividend yield of ATAI Life Sciences BV (ATAI) is 0.00%
The market capitalization of ATAI Life Sciences BV (ATAI) is $266.81M
The stock symbol (or ticker) of ATAI Life Sciences BV is ATAI